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Abstract 
BACKGROUND: Activated forms of Ras are enhanced in both breast cancer as well as the cell lines with EGFR 
and HER2 expression. Therefore, H-Ras could be activated in breast tumours in the absence of direct mutational 
activation of Ras itself and could contribute to 20-50% of the cases. Expression inhibition, signal transduction 
interruption from H-Ras to the nucleus could become a promising therapeutic target.  
AIM: The aim of this study was to investigate the clinical and morphological criteria of locally advanced breast 
cancer and the expression of H-Ras oncoprotein in patients who have been subjected to different regimens of 
farnesyltransferase inhibitor.  
METHODS: H-Ras status was assessed by immunohistochemistry (IHC). 
RESULTS: An association between the expressions of H-Ras and Her2/neu (p = 0.001) as well as the tumour 
proliferation index Ki-67 (p = 0.001) in patients with breast cancer was established. Analysis of the relationship 
between H-Ras expression showed a relatively strong association with progression-free survival both before the 
treatment (V = 0.47; p = 0.001) and after the treatment (V = 0.45; p = 0.001). These results may indicate the 
clinical applicability of H-Ras as a prognostic factor or serve as a therapeutic target for breast cancer treatment.  
CONCLUSION: These results could indicate the potential clinical application of H-Ras as a prognostic factor or a 
therapeutic target for breast cancer treatment. 
 
 
 
 
 
 
 
 
 
Introduction 
 
High heterogeneity of breast cancer highlights 
molecular nature of malignant cells as a 
fundamentally important aspect, which is connected to 
the biological behaviour of the tumour and 
characterises their growth rate, ability to invade and 
metastasise and influences disease prognosis [1], [2].  
It has been proven that mutations and certain 
genes’ rearrangements lead to the activation of 
signalling system both at the level of growth factors 
and their receptors, as well as on the downstream 
level of signal transmission along the protein cascade 
into the cell nucleus. As a result, activation of the 
signaling system on the downstream level occurs 
regardless of the involvement of the ligand and the 
receptor [3]. 
Mutational activation of RAS genes 
contributes to the formation of malignant processes in 
more than 30% of cases, which makes them one of 
the most frequent oncogenic mutations [4]. Three 
isoforms – KRAS, HRAS and NRAS, are among the 
most studied genes of the RAS family. Mutations in 
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KRAS oncogenes occupy the highest percentage of 
occurrence in colorectal cancer patients, making up to 
21,6% of cases, while NRAS makes up to 8.0% and 
HRAS is the least frequent making up to 3.3% of 
cases [5]. Spandidos D.A. showed for the first time 
that malignant breast tumours have an increased 
expression of HRAS oncogene compared to the 
corresponding samples of the normal tissue [6]. 
Further research identified an association between the 
high expression of p21 Ras oncogene in breast 
cancer and the aggressive course of the disease [7]. 
In another study, comparative analysis of HRAS 
oncogene expression of breast cancer and stomach 
cancer with regular clinical and pathological 
parameters was conducted, which revealed that high 
expression of p21 Ras oncogene in breast cancer 
patients is often associated with the tumour 
aggressiveness [8], [9], [10]. 
Although Ras rarely mutates in case of breast 
cancer, Ras is activated by various upstream 
regulators, including the epidermal growth factor 
receptors family, in particular, ErbB1 and ErbB2 [11].  
Previous studies have shown that c-Ha-Ras 
protein expression could be used as a prognostic 
marker for the breast cancer progression as well as 
patients’ stratification based on the expression status 
and risk of development of metastasis for choosing 
preoperative chemotherapy courses [12]. 
Blocking Ras signalling and H-Ras inhibition 
in breast cancer is quite promising. Considerable 
efforts have been made to develop pharmacological 
agents that block the function of Ras. One of them is a 
development of effector signalling inhibitors-Raf-MEK-
ERK and PI3K-AKT-mTOR pathways inhibitors in 
particular, which have Ras mutations. The second 
step is to inhibit the association of the Ras membrane 
alternative prenylation, whereby they are modified by 
the addition of another isoprenoid lipid, 
geranylgeraniol. Geranylgeranylated Ras-proteins 
remain functional and get transformed in the presence 
of farnesyltransferase inhibitors. Therefore, 
farnesyltransferase inhibitors have demonstrated anti-
tumor activity in breast cancer [13], [14], [15], [16], 
[17]. 
Another mechanism by which Ras could be 
activated in breast cancer is associated with 
decreased expression of RasGAP regulatory protein. 
Mutations in the NF1 gene in neurofibromatosis 
contribute to the decreased formation of RasGAP 
neurofibromin. Hence women with this pathology have 
a higher risk of breast cancer development [18], [19].  
A relatively recently discovered mechanism of 
increased H-Ras expression in breast cancer showed 
that the expression of miRNA let-7 – a negative 
regulator of the expression of H-Ras protein, is 
reduced in cancer stem cells and clinical samples. 
Studies have also shown that restoration of the 
expression of let-7 reduces the expression of H-Ras, 
cells proliferation and metastatic spread [20]. Thus, 
understanding the mechanisms of action on signalling 
pathways contributes to the detection of novel 
therapeutic targets for breast cancer treatment. We 
suggest that H-Ras could become a target for 
farnesyltransferase inhibitor, as well as in combination 
with other immunohistochemical factors, will 
contribute to the breast tumour progression.  
This study aimed to investigate the clinical 
and morphological criteria for locally advanced breast 
cancer and H-Ras oncoprotein expression in patients 
who were subjected to the different treatment 
regimens with farnesyltransferase inhibitors.  
 
 
Material and Methods 
 
The present study was conducted after ethical 
approval from the Institutional Ethics Committee 
(17/9/10/KSMU/IEC/2017). In the present study 
morphological samples of patients with histologically 
verified stage II or III of the disease, T2N1-2M0, 
T3N0-2M0 served as inclusion criteria for the study. A 
group of 100 female patients with locally advanced 
breast cancer were recruited from June 2012 to 
February 2014. Their age ranged from 29 to 78 years, 
averaged at 59 ± years. The clinical staging was 
determined by the International TNM classification 
system (7
th
 edition). The study was approved by the 
Ethics Committee of Karaganda Medical University 
(Karaganda, Kazakhstan).  
Immunohistochemical determination of H-Ras 
oncoprotein expression was done on archival 
histological material samples of patients with breast 
cancer before and after the treatment. For 
immunohistochemical studies histological paraffin 
slices up to 5 μm thick were prepared, followed by 
dewaxing, then the slices were dehydrated and 
washed in sodium citrate buffer (PBS, sc-294091, 
Santa Cruz). Immunohistochemical staining of 
prepared slices was done using the avidin-biotin 
system of antigen detection ImmunoCruz® ABC Kit 
(sc-516216) by the manufacturer instructions. To 
visualise the positive reaction 3,3-diaminobenzidine 
tetrachloride (DAB, sc-24982) was used as a 
chromogen.  
Mouse monoclonal anti-IgG1 antibodies to H-
Ras protein (sc-29, Santa Cruz) of murine, rat and 
human origin characterised by the positive reaction in 
the cytoplasm of the tumour cells were used in this 
study. Primary antibodies against H-Ras were 
substituted with a buffer (PBS) or non-immune anti-
IgG1 as a negative control. Two independent 
researchers were involved in the expression 
assessment. Positive staining on the tumour cells 
membrane and cytoplasm was considered as a 
positive test. The percentage of positively stained 
cells and the intensity of staining were evaluated. 
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Percent of positively stained cells: < 10%-0; 10-50%-
1; 51-80-2%; > 81%-3. The intensity of the staining: 
no reaction-0 points, weak reaction-1 point; moderate 
reaction-2 points, pronounced reaction – 3 points. IRS 
rating scale: 0-2 points – negative reaction; 3-4 points 
– weak reaction; 6-8 points – moderate reaction; 9-12 
points – pronounced reaction.  
Statistical analysis. The corresponding data 
are presented as a mean ± standard deviation (N = 3); 
confidence interval was calculated using Wald’s 
methods. The analysis of the significance of 
relationships between the qualitative variables was 
performed using Pearson’s chi-square criteria. 
Kramer’s correlation analysis was used to assess the 
relationship between two qualitative variables. To 
assess the relationship between the two quantitative 
variables, Spearman’s correlation method was 
performed. Statistical analysis was carried out using 
Statistica 10. P < 0.05 was considered to be an 
indicator of statistical significance.  
 
 
Results 
 
All 100 patients were females with the mean 
age of ± 59 years. The average follow-up period was 
12 months. The majority (68%) of patients had stage II 
of the disease. In 65% of cases, regional metastatic 
spread in one axillary lymph node was detected, 9%-
in two lymph nodes, 4%-in three.  
H-Ras expression was evaluated in 200 
tumour tissue samples before and after the 
neoadjuvant therapy for breast cancer. 
Immunohistochemical staining of H-Ras was 
performed (Figure 1). The immunohistochemical 
reaction was described as no reaction, a weak 
reaction and an intense reaction. According to the 
classification criteria, positive H-Ras expression was 
identified in 45 tumours (45%) before the treatment 
and in 35 tumours (35%) after the treatment. 
 
Figure 1: Immunohistochemical staining for the expression of H-Ras 
in human breast tissues of locally advanced cancer. The intensity of 
staining was described as A) no reaction; B) a weak reaction and C) 
an intense reaction (x 200 magnification) 
 
Analysis of the relationship between the H-
Ras expression before and after the treatment with 
clinical and pathological variables is summarised in 
Table 1.  
 
Table 1: Relationship between the H-Ras expression and 
clinical and morphological criteria of 100 breast cancer 
patients (p = 0.05) 
 
Features 
N H-Ras expression before the 
treatment 
p level 

2
. 
p level 
H-Ras expression after the 
treatment 
 

2
. 
p level 
Negative 
(n = 55) 
[CI, %] 
Positive 
(n = 45) 
[CI. %] 
Negative 
(n = 65) 
[CI. %] 
Positive 
(n = 35) 
[CI, %] 
 Age 
 
≤ 50 
 
29 
16  
[37.54; 71.60] 
 
 
13 
[28.40; 62.46] 
 
2.87; 
0.41 
18 
[43.95; 77.36] 
11 
[22.64; 56.05] 
2.71 
0.25 
 
> 50 
71 39 
[43.40; 65.95] 
32 [34.05; 
56.60] 
4.19 
0.37 
47 [54.59; 
76.15] 
24 [23.85; 
45.41] 
5.05 
0.16 
 Depth of tumour invasion 
Т2 65 34 
[40.38;63.98] 
31 
[36.03; 59.62] 
 
 
 
8.06 
0.62 
 
41 [50.90; 
73.79] 
24 
[26.21; 49.10] 
 
 
5.12 
0.69 
Т3 17 7 
[21.56;64.05] 
 
10 
[35.95; 78.44] 
10 
[35.95; 78.44] 
7 
[21.56; 64.05] 
 
Т4 18 13 
[48.80;87.83] 
 
5 
[12.17; 51.20] 
14 
[54.25; 91.53] 
4 
[8.47; 45.75] 
 Regional metastatic spread 
N0 16 8 
[28.00;72.00] 
8 
[28.00; 72.00] 
 
 
 
2.08 
0.83 
8 
[28.00; 72.00] 
8 
[28.00; 72.00] 
 
 
 
4.74 
0.19 
N1 66 34 
[39.71;63.15] 
32 
[36.85; 60.29] 
43 
[53.08; 75.55] 
23 
[24.45; 46.92] 
N2 11 9 
[51.15;96.01] 
2 
[3.99;48.85] 
8 
[42.89; 90.80] 
3 
[9.20; 57.11] 
N3 7 4 
[24.98;84.25] 
3 
[15.75; 75.02] 
6 
[46.65; 99.47] 
1 
[0.53; 53.35] 
 Estrogen receptors 
Negative 52 26 
[36.89;63.11] 
26 
[36.89; 63.11] 
10.80 
0.05 
 
30 
[44.18; 70.14] 
22 
[29.86; 55.82] 
5.31 
0.14 
 Positive 48 32 
[52.49;78.38] 
16 
[21.62; 47;51] 
35 
[58.89; 83.54] 
13 
[16.46; 41.11] 
 Progesterone receptors 
Negative 64 30 
[35.17;58.93] 
34 
[41.07; 64.83] 
5.17 
0.39 
40 
[50.23; 73.35] 
 
24 
[26.65; 49.77] 
1.38 
0.70 
 
Positive 36 25 
[53.03;82.11] 
11 
[17.89; 56.97] 
25 
[53.03;82.11] 
11 
[17.89; 56.97] 
 Her-2\neu status 
Negative 54 49 
[79.67;96.40] 
5 
[3.60; 20.33] 
61.68 
0.001 
 
51 
[84.30; 96.68] 
3 
[1.32; 15.70] 
51.42 
0.001 
 Positive 46 6 
[5.74; 26.04] 
40 
[73.96; 94.26] 
14 
[19.00; 44.89] 
32 
[55.11; 81.00] 
 Ki-67 proliferation index 
< 15 34 1 
[0.78; 16.22] 
 
33 
[83.78;99.78] 
265.81 
0.001 
 
1 
[0.78; 16.22] 
 
33 
[0.78; 16.22] 
 
155.04 
0.004 
 
≥ 15 66 11 
[9.39; 27.61] 
45 
[56.17; 78.19] 
21 
[21.81; 43.83] 
35 
[41.16; 64.57] 
 Therapy 
Arglabin 31 14 
[29.15;62.24] 
17 
[37.76;70.85] 
 
 
11.96 
0.28 
20 
[46.88; 78.95] 
11 
[21.05; 53.12] 
 
 
7.86 
0.44 
АС 38 23 
[44.69;74.43] 
15 
[25.57; 55.31] 
23 
[44.69; 74.43] 
15 
[25.57; 55.31] 
АС + 
Arglabin 
31 18 
[40.74;73.61] 
13 
[26.39; 59.26] 
22 
[53.25; 84.06] 
9 
[15.94; 46.75] 
АС – treatment regimen adriablastin + cyclophosphan. 
 
As a result of the performed comparative 
analysis, a statistically significant difference between 
HRAS and clinical and pathological features such as 
Her-2/neu (p = 0.001), Ki-67 proliferating index (p = 
0.001) of the patients with a verified breast cancer 
diagnosis were found.  
A study of the efficacy of the therapy showed 
a strong relationship between the sum of the 
diameters of the tumour according to the RECIST 1.1 
and percentage reduction of the tumour size (r = 0.87; 
p < 0.05) (Figure 2). 
 
Figure 2: Relationship between the sum of the diameters of the 
tumour according to the RECIST 1.1 and percentage reduction of 
the tumour size 
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According to the results of the association 
analysis of the expression ability of H-Ras oncoprotein 
with clinicopathological factors in breast cancer, a 
strong correlation with the expression of Her-2/neu 
was determined, where Kramer’s correlation 
coefficient of V = 0.78 (p = 0.001) before the treatment 
and V = 0.67 (p = 0.001) after the treatment. In 
addition, the strong correlation with the proliferative 
activity index Ki-67 and H-Ras before the treatment 
with V = 0.57 (p = 0.001) and relatively-strong 
correlation with H-Ras after the treatment with V = 
0.53 (p = 0.001) were identified. 
When analyzing the relationship between the 
H-Ras expression and progression-free survival, 
Kramer’s correlation coefficient before the treatment 
was V = 0.47 (
2 
= 68.92, p = 0.001) and V = 0.45 (
2 
= 62.11, p = 0.001) after the treatment, which 
indicates the presence of relatively strong correlation. 
Also, the correlation between the percentage of 
positively stained for H-Ras cells and progression-free 
survival (time to progression) was investigated. 
Spearman’s correlation coefficient was calculated: r = 
-0.78 before the treatment and r = -0.72 after the 
treatment. 
The relationship between H-Ras and 
progesterone receptors turned to be less pronounced 
and accounted for V = 0.32 (p = 0.06) before the 
treatment and V = 0.25 (p = 0.17) after the treatment. 
Correlation between H-Ras and estrogen receptors 
was found to be V = 0.26 (p = 0.15) before the 
treatment and V = 0.23 (p = 0.11) after the treatment, 
which is considered to be moderate, however 
considering p value, the relationship was not 
significant. 
When studying the relationship between H-
Ras with effectiveness of anti-tumor therapy according 
to the RECIST 1 criteria, Kramer’s correlation 
coefficient was V = 0.1 (p = 0.84) and V = 0.15 (p = 
0.94), the obtained results require further study. 
 
 
Discussion 
 
Ras activation in breast cancer tumour could 
occur in the presence of EGFR or HER2 without direct 
mutation in Ras itself and could account for 20-50% of 
cases [21], [22]. Thus, expression inhibition and H-
Ras to nucleus signalling interruption could become a 
promising therapeutic target. The 
immunohistochemical study had shown that in 45% of 
breast cancer cases before the treatment and 35% of 
cases after the treatment H-Ras expression was 
present. Previous research indicated that H-Ras was 
expressed in 60% of breast cancer cases, while a 
mutation in this gene attribute to only 5-10% of cases, 
which could be due to post-transcriptional regulation 
mechanisms [23], [24]. Moreover, it was shown that 
H-Ras positive breast cancer patients had a worse 
prognosis than H-Ras negative patients. Analysis of 
relationship between the H-Ras expression and 
progression-free survival indicated a relatively strong 
correlation both before the treatment (V = 0.47; p = 
0.001) and after the treatment (V = 0.45; p = 0.001). 
Correlation between H-Ras and progression-free 
survival (time to progression) before the treatment 
was r = -0.78 (p = 0.03) and after the treatment r = -
0.72 (p = 0.04). 
The results of this study showed that there is 
a correlation between H-Ras expression and 
Her2/neu expression (p = 0.001) as well as with the 
tumour proliferation index Ki-67 (p = 0.001) in patients 
with breast cancer. These results could indicate the 
potential clinical application of H-Ras as a prognostic 
factor or a therapeutic target for breast cancer 
treatment. 
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